This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pharmalink Consulting Appoints Five New Regulatory Affairs Healthcare Consultants

SHORT HILLS, N.J., Feb. 14, 2013 /PRNewswire/ -- Today, Pharmalink Consulting announced the appointment and promotion of five consultants at their offices in the UK, US and India. The appointments, which have been made in response to strong business growth experienced during 2012, enhance Pharmalink's global network of Regulatory Affairs Consultants and strengthen their position as the leading independent provider of regulatory intelligence and support to the healthcare industry.

(Logo:  http://photos.prnewswire.com/prnh/20130214/594790 )

Says Stephen Loughrey, CEO Pharmalink Consulting; "We are delighted to welcome on board some of the most respected names in the business while, at the same time, announcing the promotions of our own home grown talent. Much of our growth has been driven by the complex and evolving needs of local health authorities around the world. Our Consultants at Pharmalink can provide in-market intelligence and planning in over 100 countries which in turn gives our clients the competitive advantage they need to ensure their products are successfully registered worldwide."

Key appointments and promotions include:

  • Kevin O'Toole has been promoted to Associate Director - Commercial Operations.  Kevin has worked with Pharmalink for 7 years and has been instrumental in driving growth across all healthcare sectors.  Speaking earlier, Kevin stressed the importance of being a specialist consultancy within an increasingly complex industry.  "Unlike some other consultancies, Pharmalink specialises in Regulatory Affairs only. The healthcare landscape has evolved so much in the last 10-15 years it now requires dedicated teams of specialists to meet the demands of local health authorities around the world.  By having the right teams in place we can continue to support our customers and meet their needs with immediacy and excellence, no matter where they are located."
  • Andrew Campbell will assume the newly developed role of Senior Director, Business Development.  With previous experience at Fortune 500 companies Andrew will focus on growing the Pharmalink's North American business and will report directly to Pharmalink CEO, Stephen Loughrey.
  • Lucy Quinlan has also been at Pharmalink for 7 years and has been promoted to the role of Associate Director, Resourcing and Recruitment. She will be responsible for the recruitment of all permanent employees and the long-term strategy for company-wide resourcing and recruitment.
  • Emily Hawkins joined the Pharmalink team at the end of last year as European Recruitment Resourcer.  From the USA, Emily has a background in recruitment, and her appointment reflects the growing need for sourcing and recruiting the best consultants in the healthcare Regulatory Affairs arena.
  • Vrushali Tambe has recently joined the Pharmalink Mumbai office as a Regulatory Affairs Officer. Vrushali was previously at GSK and completed her M.Sc. from Goa University.

About Pharmalink Consulting:

Pharmalink Consulting is the leader in global Regulatory Affairs.  Established in 1998, the company has experienced rapid international growth and now has eight offices on four continents and is extremely well-placed to meet the increasingly complex needs of the healthcare regulatory environment; key areas covered include, Pharmaceuticals, Biotech, Consumer Healthcare, Medical Devices and Generics.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,970.04 +257.38 1.45%
S&P 500 2,081.64 +20.62 1.00%
NASDAQ 4,928.46 +37.2410 0.76%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs